ALCAM in Lupus
Lupus nephritis (kidney disease) is one of the most serious complications of lupus. With the TIL grant support, Dr. Mohan will build on his existing discoveries to evaluate a potential new therapeutic target for lupus nephritis. In comparing the levels of 1,100 proteins in the urine of lupus patients and healthy controls, Dr. Mohan already found several differences, and one in particular stood out. The protein ALCAM (activated leukocyte cell adhesion molecule) was consistently higher in those with lupus compared to the controls. ALCAM is a small molecule on the outside of T cells of the immune system that helps the T cells move through the tissues of the body, including the kidney.
What this study means to people with lupus Dr. Mohan will now find out how ALCAM is involved in lupus nephritis and evaluate whether it is a good target for new drug development to prevent or treat the complication.